Five Prime Therapeutics Inc
Anti-FGFR2 Antibodies in Combination with Chemotherapy Agents in Cancer Treatment
Last updated:
Abstract:
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Status:
Application
Type:
Utility
Filling date:
15 May 2018
Issue date:
12 Mar 2020